Evidence map›Paper›PMID 32252413›Full record

ArticleGenes2020

Genomics of MPNST (GeM) Consortium: Rationale and Study Design for Multi-Omic Characterization of NF1-Associated and Sporadic MPNSTs.

David T Miller, Isidro Cortés-Ciriano, Nischalan Pillay, Angela C Hirbe, Matija Snuderl, Marilyn M Bui, Katherine Piculell, Alyaa Al-Ibraheemi, Brendan C Dickson, Jesse Hart and 9 more

Abstract read
In one paragraph

Article in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

David T MillerDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-1060-1945
Isidro Cortés-CirianoEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK.ORCID 0000-0002-2036-494X
Nischalan PillayDepartment of Pathology, University College London Cancer Institute, Bloomsbury, London WC1E 6BT, UK.
Angela C HirbeOncology Division, Department of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA.ORCID 0000-0003-1719-0771
Matija SnuderlDepartment of Pathology, New York University Langone Health, New York City, NY 10016, USA.
Marilyn M BuiDepartment of Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Katherine PiculellDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.
Alyaa Al-IbraheemiDepartment of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
Brendan C DicksonDepartment of Pathology and Laboratory Medicine, Mt. Sinai Hospital, Toronto, ON M5G 1XF, Canada.ORCID 0000-0003-2269-6216
Jesse HartDepartment of Pathology, Lifespan Laboratories, Rhode Island Hospital, Providence, RI 02903, USA.
Kevin JonesDepartments of Orthopaedics and Oncological Sciences; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA.
Justin T JordanPappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Raymond H KimDepartment of Medical Oncology, Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G 2C1, Canada.ORCID 0000-0002-2147-8674
Daniel LindsayRoyal National Orthopaedic Hospital, Brockley Hill, Stanmore, Middlesex HA7 4LP, UK.
Yoshihiro NishidaDepartment of Rehabilitation, Nagoya University Hospital, Nagoya 466-8550, Aichi, Japan.
Nicole J UllrichDepartment of Neurology, Boston Children's Hospital, Boston, MA 02115, USA.
Xia WangGeneHome, Moffitt Cancer Center, Tampa, FL 33612, USA.
Peter J ParkDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
Adrienne M FlanaganDepartment of Pathology, University College London Cancer Institute, Bloomsbury, London WC1E 6BT, UK.

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Cancer Research UK 18387Department of HealthNCI NIH HHS P30 CA076292
6 · The paper itself

Abstract

The Genomics of Malignant Peripheral Nerve Sheath Tumor (GeM) Consortium is an international collaboration focusing on multi-omic analysis of malignant peripheral nerve sheath tumors (MPNSTs), the most aggressive tumor associated with neurofibromatosis type 1 (NF1). Here we present a summary of current knowledge gaps, a description of our consortium and the cohort we have assembled, and an overview of our plans for multi-omic analysis of these tumors. We propose that our analysis will lead to a better understanding of the order and timing of genetic events related to MPNST initiation and progression. Our ten institutions have assembled 96 fresh frozen NF1-related (63%) and sporadic MPNST specimens from 86 subjects with corresponding clinical and pathological data. Clinical data have been collected as part of the International MPNST Registry. We will characterize these tumors with bulk whole genome sequencing, RNAseq, and DNA methylation profiling. In addition, we will perform multiregional analysis and temporal sampling, with the same methodologies, on a subset of nine subjects with NF1-related MPNSTs to assess tumor heterogeneity and cancer evolution. Subsequent multi-omic analyses of additional archival specimens will include deep exome sequencing (500×) and high density copy number arrays for both validation of results based on fresh frozen tumors, and to assess further tumor heterogeneity and evolution. Digital pathology images are being collected in a cloud-based platform for consensus review. The result of these efforts will be the largest MPNST multi-omic dataset with correlated clinical and pathological information ever assembled.

Indexed as

Base SequenceComputational BiologyDNA MethylationExomeFemaleGenetic HeterogeneityGenomicsHumansMaleNeurofibromatosis 1Neurofibromin 1NeurofibrosarcomaProteomicsTranscriptomeNeurofibromin 1clinical geneticsgenomicsMPNSTneurofibromatosisnext generation sequencingpathologytumor evolution

Identifiers

PMID32252413
PMCPMC7231181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.